Efficacy and toxicity of particle radiotherapy in WHO grade II and grade III meningiomas: a systematic review

Neurosurg Focus. 2019 Jun 1;46(6):E12. doi: 10.3171/2019.3.FOCUS1967.

Abstract

OBJECTIVEAdjuvant radiotherapy has become a common addition to the management of high-grade meningiomas, as immediate treatment with radiation following resection has been associated with significantly improved outcomes. Recent investigations into particle therapy have expanded into the management of high-risk meningiomas. Here, the authors systematically review studies on the efficacy and utility of particle-based radiotherapy in the management of high-grade meningioma.METHODSA literature search was developed by first defining the population, intervention, comparison, outcomes, and study design (PICOS). A search strategy was designed for each of three electronic databases: PubMed, Embase, and Scopus. Data extraction was conducted in accordance with the PRISMA guidelines. Outcomes of interest included local disease control, overall survival, and toxicity, which were compared with historical data on photon-based therapies.RESULTSEleven retrospective studies including 240 patients with atypical (WHO grade II) and anaplastic (WHO grade III) meningioma undergoing particle radiation therapy were identified. Five of the 11 studies included in this systematic review focused specifically on WHO grade II and III meningiomas; the others also included WHO grade I meningioma. Across all of the studies, the median follow-up ranged from 6 to 145 months. Local control rates for high-grade meningiomas ranged from 46.7% to 86% by the last follow-up or at 5 years. Overall survival rates ranged from 0% to 100% with better prognoses for atypical than for malignant meningiomas. Radiation necrosis was the most common adverse effect of treatment, occurring in 3.9% of specified cases.CONCLUSIONSDespite the lack of randomized prospective trials, this review of existing retrospective studies suggests that particle therapy, whether an adjuvant or a stand-alone treatment, confers survival benefit with a relatively low risk for severe treatment-derived toxicity compared to standard photon-based therapy. However, additional controlled studies are needed.

Keywords: CNS = central nervous system; IMPT = intensity-modulated proton therapy; OCEBM = Oxford Centre for Evidence-based Medicine; PICOS = population, intervention, comparison, outcomes, and study design; SRS = stereotactic radiosurgery; WHO = World Health Organization; atypical; malignant; meningioma; particle radiotherapy.

Publication types

  • Systematic Review

MeSH terms

  • Alopecia / etiology
  • Brain / radiation effects
  • Carbon / therapeutic use*
  • Cations / therapeutic use
  • Combined Modality Therapy
  • Cost-Benefit Analysis
  • Cranial Irradiation* / adverse effects
  • Cranial Irradiation* / economics
  • Craniotomy
  • Follow-Up Studies
  • Humans
  • Meningeal Neoplasms / pathology
  • Meningeal Neoplasms / radiotherapy*
  • Meningeal Neoplasms / surgery
  • Meningioma / pathology
  • Meningioma / radiotherapy*
  • Meningioma / surgery
  • Necrosis
  • Photons / therapeutic use*
  • Prognosis
  • Proton Therapy* / adverse effects
  • Proton Therapy* / economics
  • Radiation Injuries / etiology
  • Radiation Injuries / therapy
  • Radiotherapy, Adjuvant / adverse effects
  • Radiotherapy, Adjuvant / economics
  • Radiotherapy, Adjuvant / methods*
  • Retrospective Studies
  • Seizures / etiology

Substances

  • Cations
  • Carbon